Immunic, Inc. Stock

$0.96

3.66% yesterday

Nasdaq, Jul 18, 10:15 pm CET

ISIN

US4525EP1011

Symbol

IMUX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Immunic, Inc. Stock price

$0.96

-14.20 93.64% 5Y

Nasdaq, Closing price Fri, Jul 18 2025

+0.03 3.66%

ISIN

US4525EP1011

Symbol

IMUX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$92.4m

Enterprise Value

$78.1m

Net debt

positive

Cash

$14.3m

Shares outstanding

90.2m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

45.1%

Return on Equity

-545.4%

ROCE

1,992.0%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-100.9m | -

EBIT

$-101.0m | $-103.7m

Net Income

$-96.4m | $-67.0m

Free Cash Flow

$-82.9m

EPS

$-1.0

FCF per Share

$-0.9

Short interest

7.9%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

Immunic, Inc. Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Immunic, Inc. forecast:

12x Buy

92%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Immunic, Inc. forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Immunic, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	18 18	8% 8% -
- Research and Development Expense	83 83	5% 5% -
EBITDA	-101 -101	5% 5% -
- Depreciation and Amortization	0.15 0.15	36% 36% -
EBIT (Operating Income) EBIT	-101 -101	5% 5% -
Net Profit	-96 -96	2% 2% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Immunic, Inc. Stock News

Positive

Proactive Investors

●

21 days ago

Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMI

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about new positive data from the company's phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS). Proactive: Hello you're watching Proactive, I'm joined by Immunic CEO Dr Daniel Vitt.

Positive

Proactive Investors

●

25 days ago

Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium

Immunic Inc (NASDAQ:IMUX) released new long-term data from an ongoing study showing that its experimental drug, vidofludimus calcium, continues to help patients with relapsing-remitting multiple sclerosis (RRMS) over time. The biotech company said 92.3% of patients remained free of 12-week confirmed disability worsening (CDW) and 92.7% free of 24-week CDW at week 144, based on data representing...

Neutral

PRNewsWire

●

25 days ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable Safety and Tolerability Profile; Long-Term Data Now Available up to 5.5 Years – NEW YORK , June 24, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pi...

More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office	United States
CEO	Daniel Vitt
Employees	91
Founded	2003
Website	imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now